

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

Claims 1-7 (canceled)

my 12-27-04
see
Examiner's
P

Claim 8. (currently amended) A method for screening a candidate medicament for treatment and/or prevention of an apoptosis-associated disease which comprises adding ^{an} ~~a~~ ^{agent} ~~candidate medicament~~ to be tested, NADE (p75NTR-associated cell death executor) and an apoptosis related protein which binds to NADE, in a system, and detecting and determining the effect on the binding between NADE and an apoptosis related protein which binds to NADE in the presence of ^{said agent} ~~a candidate medicament~~, ^{the agent} ~~wherein the candidate medicament tested~~ is selected as a candidate ~~of an effective~~ medicament when the ^{agent} ~~candidate medicament~~ inhibits or increases the ~~interaction~~ binding between NADE and ^{related} ~~an apoptosis related protein which binds to NADE and~~ wherein the apoptosis ~~relating~~ protein which binds to NADE is chosen from the group consisting of 14-3-3 protein, ING-1, NIK/HGK protein, P33 ^{ING-1} ~~ING~~ ^{relative} protein, eIF4G protein and Huntington-binding protein 1

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

Claims 1-7 (canceled)

Claim 8. (currently amended) A method for screening a candidate medicament for treatment and/or prevention of an apoptosis-associated disease which comprises adding ^{an} ~~a~~ ^{agent} ~~candidate medicament~~ to be tested, NADE (p75NTR-associated cell death executor) and an apoptosis related protein which binds to NADE, in a system, and detecting and determining the effect on the binding between NADE and an apoptosis related protein which binds to NADE in the presence of ^{said agent} ~~a candidate medicament~~, wherein ^{the agent} ~~the candidate~~ ~~medicament tested~~ is selected as a candidate ~~of an effective~~ medicament when the ^{agent} ~~candidate medicament~~ inhibits or increases the ~~interaction~~ binding between NADE and an apoptosis related protein which binds to NADE and wherein the apoptosis ~~relating~~ ^{related} protein which binds to NADE is chosen from the group consisting of 14-3-3 protein, NIK/HGK protein, P33 ^{ING-1} ~~ING~~ ^{relative} protein, eIF4G protein and Huntington-binding protein 1